The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ZoptEC: Phase III study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050).
David S. Miller
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
Hani Gabra
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
Guenter Emons
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
D. Scott McMeekin
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
Amit M. Oza
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
Sarah Madhu Temkin
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris
Ignace Vergote
Consultant or Advisory Role - Aeterna Zentaris
Research Funding - Aeterna Zentaris